Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) causes substantial respiratory disease. Bivalent RSV prefusion F (RSVpreF) vaccine is licensed in ≥60-year-olds. RSVpreF was well tolerated and immunogenic in a phase 1/2 study. We evaluated antibody persistence after initial vaccination and safety and immunogenicity after revaccination from this study.

Methods

Healthy adults were randomized to receive initial vaccination and revaccination 12 months later with either placebo or RSVpreF (240 µg with or without aluminum hydroxide). RSV-A and RSV-B geometric mean neutralizing titers (GMTs) were measured through 12 months after both vaccinations. Tolerability and safety were assessed.

Results

There were 263 participants revaccinated (18-49 years old, n = 134; 65-85 years old, n

SUBMITTER: Walsh EE 

PROVIDER: S-EPMC11481295 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature